

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL

No. 762 Session of 2021

INTRODUCED BY J. WARD, COSTA, YUDICHAK, MENSCH AND MUTH,  
JUNE 16, 2021

REFERRED TO CONSUMER PROTECTION AND PROFESSIONAL LICENSURE,  
JUNE 16, 2021

AN ACT

1 Amending the act of March 20, 2002 (P.L.154, No.13), entitled  
2 "An act reforming the law on medical professional liability;  
3 providing for patient safety and reporting; establishing the  
4 Patient Safety Authority and the Patient Safety Trust Fund;  
5 abrogating regulations; providing for medical professional  
6 liability informed consent, damages, expert qualifications,  
7 limitations of actions and medical records; establishing the  
8 Interbranch Commission on Venue; providing for medical  
9 professional liability insurance; establishing the Medical  
10 Care Availability and Reduction of Error Fund; providing for  
11 medical professional liability claims; establishing the Joint  
12 Underwriting Association; regulating medical professional  
13 liability insurance; providing for medical licensure  
14 regulation; providing for administration; imposing penalties;  
15 and making repeals," in medical professional liability,  
16 providing for enhanced information on breast implants.

17 The General Assembly of the Commonwealth of Pennsylvania  
18 hereby enacts as follows:

19 Section 1. The act of March 20, 2002 (P.L.154, No.13), known  
20 as the Medical Care Availability and Reduction of Error (Mcare)  
21 Act, is amended by adding a section to read:

22 Section 504.1. Enhanced information on breast implants.

23 (a) Physician duty.--During the first consultation between a  
24 physician and patient before breast implant surgery is

1 performed, the physician shall provide the patient with the  
2 following information in writing or in an electronic format:

3 (1) A description of the risks of breast implants and a  
4 description of the surgical procedures used in breast implant  
5 surgery.

6 (2) Notice that breast implants are not considered  
7 lifetime devices, the chance of developing complications  
8 increases over time and some complications will require more  
9 surgery.

10 (3) Manufacturer patient information materials on the  
11 implants that are to be used in the surgery, including  
12 warning requirements prescribed by the Food and Drug  
13 Administration.

14 (4) Information on surgical mesh used during breast  
15 implant surgery including mesh made of nondegradable  
16 synthetic materials, biodegradable synthetic materials or  
17 animal or human derived tissues. The information shall  
18 include a warning that no surgical mesh has been approved by  
19 the Food and Drug Administration for use with breast  
20 implants.

21 (5) Information on breast implant-associated anaplastic  
22 large cell lymphoma, including notice that breast implant-  
23 associated anaplastic large cell lymphoma occurs more  
24 commonly in patients with textured breast implants than  
25 smooth implants and that deaths have occurred.

26 (6) Information on breast implant illness, with the use  
27 of the breast implant patient checklist described in  
28 subsection (d).

29 (7) Information on the systemic symptoms associated with  
30 breast implants.

1       (8) Information on the national breast implant registry.

2       (9) Information on how a patient can report adverse  
3       events associated with breast implants through the Food and  
4       Drug Administration's MedWatch program or similar program.

5       (b) Breast implant information.--The information provided  
6       under subsection (a) shall be based on the information that is  
7       generally available to physicians who specialize in breast  
8       implant surgery.

9       (c) Informed consent.--After providing the information  
10       required under subsection (a), a physician shall obtain written  
11       informed consent for the procedure from the patient before  
12       performing the breast implant surgery.

13       (d) Breast implant patient checklist.--The department shall  
14       transmit notice to the Legislative Reference Bureau for  
15       publication in the Pennsylvania Bulletin of the breast implant  
16       patient checklist, and any change to the breast implant patient  
17       checklist shall be transmitted by the department separately as a  
18       notice to the Legislative Reference Bureau for publication in  
19       the Pennsylvania Bulletin. The department shall publish and  
20       maintain the complete breast implant patient checklist on the  
21       department's publicly accessible Internet website.

22       (e) Violation.--A violation of this section constitutes  
23       unprofessional conduct under the the act of October 5, 1978  
24       (P.L.1109, No.261), known as the Osteopathic Medical Practice  
25       Act, and the act of December 20, 1985 (P.L.457, No.112), known  
26       as the Medical Practice Act of 1985.

27       (f) Definitions.--As used in this section, the following  
28       words and phrases shall have the meanings given to them in this  
29       subsection unless the context clearly indicates otherwise:

30       "Breast implant patient checklist." A standardized informed

1 consent checklist developed by an international group of  
2 professional societies and patient advocacy organizations, based  
3 on recommendations by the Food and Drug Administration's  
4 guidance on breast implants, that includes information relating  
5 to:

6 (1) Breast implant-associated anaplastic large cell  
7 lymphoma.

8 (2) Breast implant illness.

9 (3) The systematic symptoms associated with breast  
10 implants.

11 (4) The national breast implant registry.

12 "Breast implant surgery." The surgical placement of a  
13 cosmetic breast implant.

14 "Department." The Department of State of the Commonwealth.

15 "National breast implant registry." A database established  
16 by a national organization of plastic surgeons in the United  
17 States, in collaboration with the Food and Drug Administration,  
18 patients and breast implant manufacturers that:

19 (1) is designed to strengthen the postmarket  
20 surveillance infrastructure for current and future breast  
21 implant devices in the United States; and

22 (2) is a quality improvement initiative and safety  
23 surveillance registry that collects clinical, procedural and  
24 outcomes data at the time of operation and subsequent  
25 reoperations for patients receiving breast implants in the  
26 United States.

27 "Physician." An individual who is licensed to practice  
28 medicine and perform breast implant surgery in this  
29 Commonwealth.

30 Section 2. This act shall take effect January 1, 2022, or

1 immediately, whichever is later.